Anterior Segment Anatomic Parameters for Risk Profiling of Primary Angle-closure Glaucoma (NCT06143943) | Clinical Trial Compass
CompletedNot Applicable
Anterior Segment Anatomic Parameters for Risk Profiling of Primary Angle-closure Glaucoma
China168 participantsStarted 2022-11-22
Plain-language summary
The goal of this observational study is to examine the anterior segment anatomical parameters associated with the scleral spur and cornea for risk profiling of primary angle-closure glaucoma (PACG). The main question it aims to answer is:
• Are there new anatomical parameters of the anterior segment of the eye that can be used early for risk profiling for PACG? Researchers will compare PACG and narrow angle groups to see if there are some anatomical parameters that can distinguish the two.
Who can participate
Age range
30 Years – 92 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Primary angle-closure glaucoma （PACG) was defined as an occlusion angle with peripheral anterior synechiae and intraocular pressure (IOP) \> 21 mmHg or associated with glaucomatous optic neuropathy. The following conditions were identified as possible glaucomatous optic neuropathies, including a vertical cup-to-disc ratio ≥ 0.6, vertical cup-to-disc ratio asymmetry ≥ 0.2, optic disc haemorrhage, and visible retinal nerve fibre layer defect.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This study looked at specific anatomical measurements of the eye — like the trabecular scleral-spur angle — to assess risk for angle-closure glaucoma. Based on my own eye anatomy, would measurements like these help clarify my personal risk level?
2Since this trial is already completed, has my doctor seen or reviewed any findings from it that might be relevant to how my angle-closure glaucoma is being assessed or managed?
3This study focused on 'risk profiling' — meaning identifying who is more likely to develop angle-closure glaucoma before it progresses. Does my current diagnosis put me at a stage where this kind of anatomical risk assessment would still be useful for my care plan?
4Are there imaging tests or measurements of my eye's anterior segment — the front part of the eye that this study focused on — that my doctor is already using or could use to better understand my situation?
5Given that this was an observational study measuring eye anatomy rather than testing a treatment, should I also be asking about separate clinical trials that are testing actual interventions for angle-closure glaucoma?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.